BS_0HW7W7SD
Embryonal tumors
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Embryonal tumors
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Embryonal tumors
- overall_survival_months
- 3.0223390275952693
- age_years
- 0.06
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.559
- MYC_TARGETS_V1+0.553
- MYC_TARGETS_V2+0.526
- G2M_CHECKPOINT+0.507
- GLYCOLYSIS+0.353
- DNA_REPAIR+0.339
- WNT_BETA_CATENIN_SIGNALING+0.305
- TGF_BETA_SIGNALING+0.284
- UNFOLDED_PROTEIN_RESPONSE+0.272
- MTORC1_SIGNALING+0.267
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.566
- INTERFERON_GAMMA_RESPONSE-0.518
- IL6_JAK_STAT3_SIGNALING-0.437
- ALLOGRAFT_REJECTION-0.381
- INFLAMMATORY_RESPONSE-0.373
- COMPLEMENT-0.328
- KRAS_SIGNALING_UP-0.297
- TNFA_SIGNALING_VIA_NFKB-0.288
- MYOGENESIS-0.256
- HEDGEHOG_SIGNALING-0.249
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_74FS6GMW | ATRT | — | 0.893 |
| 2 | TCGA-MF-A522-01A-11R-A262-07 | — | cohortSQ2 | 0.886 |
| 3 | MBCProject_6109_T1B_RNA | — | B | 0.858 |
| 4 | TCGA-DK-A3IM-01A-11R-A20F-07 | — | — | 0.858 |
| 5 | SJEPD001513_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.852 |
| 6 | BS_TZ5D0A7R | Supratentorial Ependymoma | — | 0.852 |
| 7 | BS_4SCWT0FX | Ependymoma NOS | — | 0.850 |
| 8 | BS_MDBT7S5Z | high-grade glioma | — | 0.849 |
| 9 | TCGA-85-8664-01A-11R-2403-07 | — | cohortMD1 | 0.849 |
| 10 | C3N-04155 | — | cohortSQ2 | 0.849 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.559 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.553 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.526 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.507 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.353 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.339 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.305 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.284 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.272 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.267 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.235 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.179 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.175 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.108 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.102 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.091 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.074 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.061 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.054 | Remibrutinib | — uncovered |